• Find a Doctor
  • International Patients
  • Newsroom
  • Contact Us
  • Patients & Families
  • Education
  • Research
  • Departments & People
  • Donate to The Barrow

    David Brachman, MD

    Radiation Oncologist (602) 406-6761

    Dr. Brachman has training in both Cyberknife and Gamma Knife stereotactic radiosurgery. Dr. Brachman has taught as both an instructor and assistant professor in the Department of Radiation and Cellular Oncology at the University of Chicago. He earned his medical degree at Loyola University of Chicago, Stritch School of Medicine, and completed his residency in internal medicine at Michael Reese Hospital in Chicago.

    Dr. Brachman completed a second residency in radiation oncology at the Department of Radiation and Cellular Oncology at the University of Chicago and is board certified in radiation oncology by the American Board of Radiology. He is a fellow of the American College of Radiation Oncology and has published extensively in his field.

    Education & Training
    • Radiation Oncology Residency, Michael Reese/University of Chicago, 1987-1990
    • Internship and Residency, Internal Medicine, Michael Reese Hospital & Medical Center, 1982-1985
    • MD, Loyola University of Chicago Stritch School of Medicine, 1982
    • BS, University of Illinois Urbana-Champaign, Biology, 1978
    Professional Memberships
    • American College of Radiation Oncology (ACRO)
    • American Society for Therapeutic Radiology and Oncology (ASTRO)
    • American Association for Cancer Research (AACR)
    • Radiation Therapy Oncology Group (RTOG)
    Honors and Awards
    • Fellow, American College of Radiation Oncology, 2003
    • American Cancer Society Career Development Award, 1993
    • American Society of Clinical Oncology Travel Award, 1991
    • Alpha Omega Alpha, Stritch School of Medicine, 1982
    • Edmund J. James Scholar, University of Illinois, 1978
    Selected Publications
    1. Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade GliomaN Engl J Med. 2016 Apr 7;374(14):1344-55.
    2. Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Mehta M, Curran W. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. Jul 1 2010;77(3):662-669.
    3. Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ, Jr., Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP. A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys. May 1 2008;71(1):79-86.
    4. Corn BW, Moughan J, Knisely JP, Fox SW, Chakravarti A, Yung WK, Curran WJ, Jr., Robins HI, Brachman DG, Henderson RH, Mehta MP, Movsas B. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. Int J Radiat Oncol Biol Phys. May 1 2008;71(1):71-78.
    5. Lekovic GP, Gonzalez LF, Shetter AG, Porter RW, Smith KA, Brachman D, Spetzler RF. Role of Gamma Knife surgery in the management of pineal region tumors. Neurosurg Focus. 2007;23(6):E12.
    6. Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI, Meredith R, Foote R, Brachman D, Lee N. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. J Support Oncol. May 2006;4(5):252-258.
    7. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol. Jan 2006;8(1):47-52.
    8. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. Jun 20 2006;24(18):2707-2714.
    9. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ, Jr. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. Nov 1 2004;60(3):853-860.
    10. Fisher J, Scott C, Scarantino CW, Leveque FG, White RL, Rotman M, Hodson DI, Meredith RF, Foote R, Brachman DG, Lee N.Phase III quality-of-life study results: impact on patients’ quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer–RTOG 97-09. Int J Radiat Oncol Biol Phys. Jul 1 2003;56(3):832-836.

    About Barrow

    Since our doors opened as a regional specialty center in 1962, we have grown into one of the premiere destinations in the world for neurology and neurosurgery. Our experienced, highly skilled, and comprehensive team of neurological specialists can provide you with a complete spectrum of care–from diagnosis through outpatient neurorehabilitation–under one roof. Barrow Neurological Institute: Discover. Educate. Heal.